Novo Nordisk joined the many pharmaceutical companies pushing back on government-negotiated drug pricing in the United States.

While much of the recent GLP-1 saga has been written in the U.S., Novo Nordisk continues to expand its semaglutide empire ...

At the recent ATTD 2025 meeting, participants discussed recent progress and remaining challenges in developing a fully closed ...

In addition to the newsworthy headlines above, the PR Newswire team identified several trends shaping health industry news in ...

The global disposable insulin-delivery device market is projected to experience robust growth over the next decade, according to recent industry insights. Valued at USD 14,585.6 million in 2022, the ...

CoreWeave, Inc. Class A Common Stock, Blackstone, BlackRock, Novo Nordisk A/S, Apollo Global Management, Prologis, and ...

DexCom DXCM recently signed a licensing and data partnership with a privately held healthcare-at-home digital diagnostics company — Nanowear. Per the terms of the agreement, Nanowear will use glucose ...

An advanced hybrid closed-loop insulin delivery system is safe to use for pregnant women with type 1 diabetes and may provide ...

The Business Research Company Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout. LONDON, GREATER ...

Are we truly on the brink of a cure for obesity? Or could neglecting the root causes risk worsening the very problems we seek ...

1 "We are thrilled that Novo Nordisk, a global leader in diabetes care and obesity management, has recognized the potential of LX9851," said Mike Exton, PhD, CEO, director, Lexicon, in a press release ...